Comparison of respiratory pathogens in children with community-acquired pneumonia before and during the COVID-19 pandemic.
COVID-19
Children
Pneumonia
Prevalence
Respiratory pathogens
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
27 10 2023
27 10 2023
Historique:
received:
18
03
2023
accepted:
11
08
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
Multifaceted non-pharmaceutical interventions during the COVID-19 pandemic have not only reduced the transmission of SARS-CoV2, but have had an effect on the prevalence of other pathogens. This retrospective study aimed to compare and analyze the changes of respiratory pathogens in hospitalized children with community-acquired pneumonia. From January 2019 to December 2020, children with community-acquired pneumonia were selected from the Department of Respiratory Medicine, Shanghai Children's Medical Center. On the first day of hospitalization, sputum, throat swabs, venous blood samples from them were collected for detection of pathogens. A total of 2596 children with community-acquired pneumonia were enrolled, including 1871 patients in 2019 and 725 in 2020. The detection rate in 2020 was lower than in 2019, whether single or multiple pathogens. Compared with 2019, the detection rate of virus, especially parainfluenza virus, influenza virus and respiratory syncytial virus, all decreased in 2020. On the contrary, the prevalence of human rhinovirus was much higher than that in 2019. In addition, the positivity rate for bacteria did not change much over the two years, which seemed to be less affected by COVID-19. And Mycoplasma pneumoniae which broke out in 2019 has been in low prevalence since March 2020 even following the reopening of school. Strict public health interventions for COVID-19 in China have effectively suppressed the spread of not only SARS-CoV2 but parainfluenza virus, influenza virus and Mycoplasma pneumonia as well. However, it had a much more limited effect on bacteria and rhinovirus. Therefore, more epidemiological surveillance of respiratory pathogens will help improve early preventive measures.
Sections du résumé
BACKGROUND
Multifaceted non-pharmaceutical interventions during the COVID-19 pandemic have not only reduced the transmission of SARS-CoV2, but have had an effect on the prevalence of other pathogens. This retrospective study aimed to compare and analyze the changes of respiratory pathogens in hospitalized children with community-acquired pneumonia.
METHODS
From January 2019 to December 2020, children with community-acquired pneumonia were selected from the Department of Respiratory Medicine, Shanghai Children's Medical Center. On the first day of hospitalization, sputum, throat swabs, venous blood samples from them were collected for detection of pathogens.
RESULTS
A total of 2596 children with community-acquired pneumonia were enrolled, including 1871 patients in 2019 and 725 in 2020. The detection rate in 2020 was lower than in 2019, whether single or multiple pathogens. Compared with 2019, the detection rate of virus, especially parainfluenza virus, influenza virus and respiratory syncytial virus, all decreased in 2020. On the contrary, the prevalence of human rhinovirus was much higher than that in 2019. In addition, the positivity rate for bacteria did not change much over the two years, which seemed to be less affected by COVID-19. And Mycoplasma pneumoniae which broke out in 2019 has been in low prevalence since March 2020 even following the reopening of school.
CONCLUSIONS
Strict public health interventions for COVID-19 in China have effectively suppressed the spread of not only SARS-CoV2 but parainfluenza virus, influenza virus and Mycoplasma pneumonia as well. However, it had a much more limited effect on bacteria and rhinovirus. Therefore, more epidemiological surveillance of respiratory pathogens will help improve early preventive measures.
Identifiants
pubmed: 37891511
doi: 10.1186/s12887-023-04246-0
pii: 10.1186/s12887-023-04246-0
pmc: PMC10605329
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
535Informations de copyright
© 2023. The Author(s).
Références
Medicine (Baltimore). 2019 May;98(18):e15419
pubmed: 31045799
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Med Virol. 2012 Mar;84(3):543-7
pubmed: 22246844
Lancet Public Health. 2020 May;5(5):e279-e288
pubmed: 32311320
Front Cell Infect Microbiol. 2022 Apr 29;12:854505
pubmed: 35573799
Front Cell Infect Microbiol. 2022 Mar 21;12:843463
pubmed: 35386684
J Bacteriol. 1969 Aug;99(2):491-5
pubmed: 5808076
Nat Med. 2020 May;26(5):676-680
pubmed: 32371934
Pediatr Transplant. 2021 Aug;25(5):e14025
pubmed: 33904211
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
J Clin Microbiol. 2016 May;54(5):1400-1
pubmed: 26912752
J Clin Virol. 2021 Apr;137:104795
pubmed: 33761423
Curr Opin Virol. 2018 Feb;28:142-151
pubmed: 29452994
PLoS Pathog. 2017 Jun 22;13(6):e1006419
pubmed: 28640898
J Infect. 2014 Apr;68(4):363-71
pubmed: 24291062
Microbes Infect. 2022 Feb;24(1):104911
pubmed: 34871774
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
BMC Pediatr. 2021 Apr 28;21(1):202
pubmed: 33910509
Euro Surveill. 2012 Feb 02;17(5):
pubmed: 22321134
J Med Internet Res. 2020 Aug 20;22(8):e21257
pubmed: 32750008
Lancet Child Adolesc Health. 2020 Nov;4(11):e42-e43
pubmed: 32956616
J Med Virol. 2020 Jul;92(7):755-769
pubmed: 32237160
PLoS One. 2017 Mar 10;12(3):e0173409
pubmed: 28282391
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Nat Rev Microbiol. 2021 Aug;19(8):528-545
pubmed: 33753932
Arch Dis Child. 2005 Jul;90(7):741-6
pubmed: 15855178
Influenza Other Respir Viruses. 2020 Nov;14(6):647-657
pubmed: 31670892
J Infect. 2021 Sep;83(3):281-293
pubmed: 34161818
Nat Commun. 2021 Feb 12;12(1):1001
pubmed: 33579926
Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):27142-27150
pubmed: 31843887